INTRODUCTION
Ultrasound-guided biopsy, particularly systematic sextant biopsy, has come to be quite widely used for detecting prostate cancer (1). This technique involves sampling as much of the peripheral zone as possible (2) (3) (4) . Error in sampling may consequently occur since the transition zone of the prostate is the site of origin of as many as 30% of all adenocarcinomas (5) . Approximately 10-40% of prostate cancers with a tumor volume <6 cm-' may be undetected by systematic sextant biopsy according to a computer simulation model (4) . To minimize sampling error as much as possible, extensive transition zone sampling alongside standard systematic sextant biopsy has been proposed. Lui et al. reported additional transition zone sextant biopsy alone to be diagnostic in 26.4% of 72 cancers (6) , though this was not confirmed in other studies (7) (8) (9) (10) (11) (12) .
Prostate cancer has become the ninth most common cause of male cancer death in Japan (13). Better biopsy techniques would lead to earlier and greater detection, thus increasing the chance of cure. The indication for transition zone biopsy in elderly Japanese males, who have a lower incidence of and mortality from prostate cancer than do their counterparts in the West, is not adequately understood (13). The present study, the first of its kind, examines the usefulness of and indication for transition zone biopsy in addition to standard systematic sextant peripheral zone biopsy for Japanese males.
SUBJECTS AND METHODS
Of 629 consecutive patients without previous diagnosis of prostate cancer and who had undergone transrectal ultrasoundguided needle biopsy at this Institution between October 1994 and November 1996, 344 underwent transition zone biopsy as well as systematic biopsy, serum prostate specific antigen (PSA) determination, digital rectal examination and transrectal ultrasound imaging. All patients whose digital rectal examination appeared questionable, or whose serum PSA was >2.0 ng/ml, underwent biopsy. An arbitrarily chosen lower PSA cut-off value of 2.0 ng/ml is used at our Institution as an indication for biopsy, rather than that (0-4.0 ng/ml) recommended by the manufacturer of the assay kit (Dainapack IMx PSA, Dinabot, Tokyo) (14) (15) (16) (17) . Biopsy was indicated partly on the basis of preprostatectomy evaluation in some patients regardless of clinical fmdings. Indication of transition zone biopsy was based on on-site assessment of the individual patient's tolerance and feelings toward his condition. The clinical stage of cancer was determined in accordance with the TNM classification (18). Subsequent to standard sextant biopsy of the peripheral zone (l), two additional biopsies were conducted anteriorly in the transition zone. To obtain transition zone tissue, the needle was inserted into the mid-portion of each half of the prostate and manually pushed through the peripheral zone. The needle was fired on reaching the transition zone boundary. All transition zone biopsies contained tissue from the left and right sides of the anterior prostate. In certain cases, additional biopsies of suspicious areas noted on ultrasound images or in digital rectal examination were carried out. Antimicrobial prophylaxis was administered in all cases, along with 500 mg of oral ciprofloxacin, twice a day for 2 days from immediately before the biopsy. No Fleet enema was conducted.
Fisher's exact probability, X 2 and Kruskal-Wallis tests were carried out for comparison, with p < 0.05 being taken as significant.
RESULTS
Prostate biopsy showed that 55 of the 344 patients (16.0%) had cancer. In 33 of these 55 patients (60.0%), both types of biopsy were positive. The standard systematic sextant peripheral zone biopsy alone demonstrated cancer in a further 20 (36.4%) and the transition zone biopsy alone was positive in two others (3.6%) ( Table 2, 3) . Of the 60 Group 1 patients with palpable abnormality, 35 (58.3%) were positive for prostate cancer. Among these 35 patients, both biopsies were positive in 20 (57.1%), the standard systematic sextant biopsy alone indicated cancer in a further 13 (37.1%) and the transition zone biopsy results alone were positive in two others (5.7%) ( Table 2 ). The 35 cancers were classified clinically as stages T2aNOMO in three, T2bNOMO in 16, T2bNxMl in two, T2bNxMx in one, T2cNOMO in one, T2cNOM1 in three, T3cNOMO in one, T3cN2MO in one, T3cNxMO in one and T3cNOMI in six patients. BPH, benign prostatic hyperplasia; PSA, prostate specific antigen; PSAD, prostate specific antigen density; TZ, transition zone.
Of the 233 Group 2 patients with palpably benign glands, 15 had prostate cancer (6.4%). For seven of these 15 patients (46.7%), standard systematic sextant biopsy alone demonstrated cancer. No cancer was indicated by transition zone biopsy alone. Both biopsies were positive in eight patients (53.3%). The 15 cancers were classified clinically as stages TlcNOMO in 12, T1cNxMx in one, T3cNOMO(nonpalpable but visible) in one and T4aNOM1 (nonpalpable but visible) in one patient. Eleven patients with negative biopsy results underwent transurethral resection of the prostate but none of these cases showed cancer.
Prostatic intraepithelial neoplasia (PIN) (19) was found in 8.3%
of patients in Group 1 (5/60, low grade in four, high grade in one) and 4.3% of patients in Group 2 00/233, low grade in eight, high grade in two). All were found in cores from the peripheral zone. No atypical adenomatous hyperplasia was found.
Of the above 293 patients, for those~49 years old, 50-59, 60-69, 70-79 and~80 years, positive biopsy results were seen in 0%, 9.1%, 14.2%, 21.2% and 35.0% respectively ( Table 2) . No statistically significant correlation was found between age and positive results (p = 0.318). Rectal findings were significant for predicting prostate cancer (p < 0.001) and positive results increased with PSA levels: 7.1% for s2.0 ng/rnl, 10.9% for 2.1-10.0 ng/rnl and 40.6% for~10.1 ng/ml (p = 0.001). The same was noted for PSAD: 3.9% for patients with PSAD s0.15 ng/ml.cm-' versus 32.8% for PSAD >0.15 ng/ml.cm'' (p < 0.001). Neither transition zone volume nor glandular volume gave an indication of prostate cancer (p =0.133 and 0.513 respectively). Transition zone biopsies disclosed cancer for PSAD >0.15 ng/ml.cm' and transition zone volume s30 cm-' in most of these patients.
One of the two patients whose cancer was indicated only by transition zone biopsy underwent radical prostatectomy for clinical stage T2b disease. The surgical specimen showed anterolaterally located peripheral zone cancer foci with poorly differentiated histology. No transition zone cancer could be detected.
Of the 51 Group 3 patients with prior negative biopsy, five (9.8%) had cancer (Table 3 ). Both biopsies gave positive results for these patients. Transition zone biopsy alone disclosed no cancer. These five cancers were classified clinically as stages TlcNOMO in three, T2bNOMO in one and T3cNOMO in one patient. No statistically significant correlation could be found between age and positive results (p = 0.899). Positive biopsy results increased with PSA: 0.0% for~2.0 ng/ml, 2.6% for 2.1-10.0 ng/ml and 36.4% for~10.1 ng/ml (p =0.015). The PSAD significantly predicted prostate cancer: 0.0% for patients with PSAD~0.15 ng/ml.cm-' versus 21.7% for PSAD >0.15 ng/ ml.cm-' (p = 0.028). No such prediction could be made from transition zone or glandular volume (p = 0.370 and 0.108 respectively). Both biopsies disclosed cancer for PSAD >0.15 ng/ml.cm-' and transition zone volume~30 cm-' in these patients. BPH, benign prostatic hyperplasia; PSA, prostate specific antigen; PSAD, prostate specific antigen density; TZ, transition zone; PIN, prostatic intraepithelial neoplasia There were eight cases (15.7%) of PIN found in Group 3 patients. Previous biopsies alone contained PIN in three patients (low grade in two and high grade in one), while only repeat biopsy cores contained PIN in four patients (low grade in two, high grade in two). One patient had high grade PIN in both the first and subsequent biopsies. All but two cases had PIN in cores taken from the peripheral zone, these two cases having PIN in cores from the transition zone. None of the four patients with PIN in the first biopsies had cancer in subsequent biopsies (Table 3 ). There was no atypical adenomatous hyperplasia.
Of the 55 patients with prostate cancer, 25 underwent radical prostatectomy.Directed biopsy from suspicioushypoechoic lesions, in addition to transition zone and sextant biopsies, was conducted in two of these 25 patients. One hypoechoic lesion was positive for cancer. Sextant biopsy cores also contained cancerous tissues though cores from the transition zone did not.
None of the patients in this study experienced febrile complication due to bacteremia. In approximately two-thirds of the patients (67.8%), transient macroscopic hematuria was noted for up to 2 weeks following biopsy (mean 3.4 days, range 0-14). No cystoscopy or clot evacuation was required. Only seven (19.4%) of 36 patients capable of ejaculation within one month following biopsy reported hematospennia.
DISCUSSION
Views differ as to the value of transition zone biopsy (Table 4) (6-12). Lui et al. (6) found additional transition zone biopsy alone to bediagnostic in 10.2% of 187 patients, this being 26.4% of all cancers detected. Following standard sextant biopsy, all patients in their study underwent an additional six biopsies anteriorly in the transition zone. Median PSA for these cases was 15.9 ng/ml [converted to Hybritech monoclonal assay level from the polyclonal value of 26.7 ng/ml (20) ]. The same investigators recently re-examined the efficacy of routine transition zone biopsy and noted cancer only in the transition zone in just 0.6% of 161 patients (12). Keetch and Catalona (7) noted that all 166 men subjected to PSA-based screening for prostate cancer had an elevated PSA (2::4.1 ng/ml, Hybritech assay). These men had previously undergone one or two sets of negative peripheral zone biopsies. They underwent four additional biopsies anteriorly in the transition zone where just two (l 0.5%) of 19 cancers were detected only in the transition zone. (9) found one (9.1%) of 11newly diagnosed cancers to be only in the transition zone. The percentage of free PSA was of no use for distinguishing patients with positive transition zone biopsy results. Fleshner and Fair (11) also investigated indications for transition zone biopsy. Eight of 58 cancers were found only in the transition zone, None of the analyzed risk factors was significantly greater in men with isolated transition zone cancer. Cancers detected by transition zone biopsy were thus 7.6% (1. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] .4%) of all cancers on average; this is too small to justify routine use (Table 4) . It may thus be concluded that transition zone biopsy would not contribute significantly to the detection of prostate cancer. The present study, on 344 Japanese patients with abnormal rectal fmdings, elevated PSA and/or previous negative biopsy, confirms this conclusion. Of 55 patients in whom prostate cancer was found, in only two (3.6%) was the cancer detected by transition zone biopsy alone.
More positive results for transition zone biopsy were obtained in the study of Lui et al (6) , possibly due to patient selection, differences in biopsy techniques and/or racial differences. Higher PSA may account to some extent for the difference (Table 4 ) (6) (7) (8) (9) (10) (11) (12) . However, the latest report from the same Institution, which showed a much lower positive transition zone biopsy rate, had greater values of this parameter (12) . Differences in cancer detection rates could thus not be due only to differences in PSA. Keetch and Catalona evaluated the results of population screening whilst others evaluated patients who had been referred to urology clinics (6) (7) (8) (9) (10) (11) (12) . Transition zone biopsy may detect tumors more efficiently for certain patients with higher incidence of prostate cancer. Lui et al. conducted more extensive sampling of the transition zone than was carried out in other studies (6) . The number of biopsy cores was a significant determinant of the rate of positive findings in a computer-assisted analysis (21) . Fewer cores would result in less accurate data for anteriorly located transition zone cancers.
The positive biopsy rate in the present study was lower than in Western studies (Table 4 ). This may in part reflect the lower incidence of prostate cancer in the Japanese male population, which could be due to racial differences in the prevalence and distribution of cancer foci (13). However, this is unlikely since a previous study failed to demonstrate racially-based differences in morphology or distribution of prostate cancer foci in radical prostatectomy specimens (17) .
Various factors may contribute to the inadequacy of transition zone biopsy. Fewer samples are covering a larger area in transition zone than in peripheral zone biopsy. Nodules of benign prostatic hypertrophy may resist needle penetration. Selective sampling of internodular rather than glandular tissue is conducted in transition zone biopsy owing to curvature of the needle track, making cancer detection less likely (22) .
The patients who would benefit most from additional use of transition zone biopsy would be those with exclusively transition zone cancers. However, transition zone cancer without cancer foci elsewhere in the gland is infrequent owing to the multifocality of prostate cancer. Tumors of transition zone origin were found in 19.6% of surgical specimens from 107 consecutive radical prostatectomies for resectable prostate cancer (TIa-b, 4; TIc, 31; T2, 52; T3, 20) at this Institution. Of these, only 6.5% (7/107) had cancer exclusively in the transition zone (unpublished data). Greene et al. (23) found peripheral zone cancer in 93% of stage A and all stage B prostate cancer specimens. Peripheral zone cancer averaged 1.94 cm-' in stage A and 3.99 cm-' in stage B disease. Transition zone cancers were present in 81% and 43% of these patients respectively,indicating the infrequency of 'pure' transition zone cancers. Quite possibly, fewer than 10% of patients would benefit from this type of biopsy. Even so, this is a maximum estimate since some transition zone cancers can be sampled by systematic sextant peripheral zone biopsy as well. During peripheral zone biopsy, the needle may penetrate the transition zone and needle biopsy of this zone may include tissue from the peripheral zone. It is significant that all seven 'pure' transition zone cancers in our radical prostatectomy series were detected by systematic sextant peripheral zone biopsy. This was also evident in one patient from the present study, whose transition zone biopsy was positive although in the radical prostatectomy specimen there were only anterolaterally located multiple peripheral zone cancer foci.
The incidence of PIN in needle biopsy ranges from 7.6 to 31% in various reports, depending on the population (19) . The incidence in this study was slightly lower, 5-7%. In contrast to previous fmdings, PIN was not associated with cancer in subsequent biopsies. These findings may be an indication of racial differences, but the number of patients is too small to draw any defmitive conclusions. Two additional cores from the transition zone did not lead to greater morbidity of biopsy.The incidence of complications was essentially that in the previous study (24) .
The present data are consistent with previous findings that transition zone biopsy does not contribute significantly to the detection of prostate cancer. Though possibly of value for certain patients, the small number of cases found to have cancer only in the transition zone in this study did not allow us to specify groups. Those with markedly elevated or rapidly increasing PSA and previous negative peripheral zone sextant biopsy results may possibly benefit from this procedure. Transurethral resection or extensive sampling of the transition zone may be indicated for such cases. The positive results of transition zone biopsy are but few and thus would not justify its routine use on Japanese patients. Further investigation should be made of patients who would benefit most from two or more biopsies of the transition zone.
